5-((3-Isopropylphenoxy)methyl)-3-phenyloxazolidin-2-one | 1228455-08-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-((3-Isopropylphenoxy)methyl)-3-phenyloxazolidin-2-one
• 英文别名: 3-phenyl-5-[(3-propan-2-ylphenoxy)methyl]-1,3-oxazolidin-2-one
• CAS: 1228455-08-0
• 化学式: C₁₉H₂₁NO₃
• 分子量: 311.381
• InChiKey: ZECGWTJFMJGWGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-异丙基苯酚 、 5-(羟基甲基)-3-苯基噁唑啉-2-酮 在 偶氮二甲酸二异丙酯 作用下， 以 二氯甲烷 为溶剂， 生成 5-((3-Isopropylphenoxy)methyl)-3-phenyloxazolidin-2-one
  参考文献：
  名称：

  3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts

  摘要：

  Hit to lead optimization of (5R)-5-hexyl-3-phenyl-1,3-oxazolidin-2-one as a positive allosteric modulator of mGluR2 is described. Improvements in potency and metabolic stability were achieved through SAR on both ends of the oxazolidinone. An optimized lead compound was found to be brain penetrant and active in a rat ketamine-induced hyperlocomotion model for antipsychotic activity. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.03.089

文献信息

• 3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts
  作者：Edward J. Brnardic、Mark E. Fraley、Robert M. Garbaccio、Mark E. Layton、John M. Sanders、Chris Culberson、Marlene A. Jacobson、Brian C. Magliaro、Pete H. Hutson、Julie A. O’Brien、Sarah L. Huszar、Jason M. Uslaner、Kerry L. Fillgrove、Cuyue Tang、Yuhsin Kuo、Sylvie M. Sur、George D. Hartman

  DOI：10.1016/j.bmcl.2010.03.089

  日期：2010.5

  Hit to lead optimization of (5R)-5-hexyl-3-phenyl-1,3-oxazolidin-2-one as a positive allosteric modulator of mGluR2 is described. Improvements in potency and metabolic stability were achieved through SAR on both ends of the oxazolidinone. An optimized lead compound was found to be brain penetrant and active in a rat ketamine-induced hyperlocomotion model for antipsychotic activity. (C) 2010 Elsevier Ltd. All rights reserved.